Immunovant Financial Statements From 2010 to 2021

Immunovant financial statements provide useful quarterly and yearly information to potential Immunovant investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunovant financial statements helps investors assess Immunovant's valuation, profitability, and current liquidity needs.
Immunovant does not presently have any fundamental trends for analysis.
.

Immunovant Financial Statements 

 
Refresh
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant main balance sheet or income statement drivers, such as Interest Expense of 559.2 K, Operating Expenses of 96 M or Research and Development Expense of 63.6 M, as well as many exotic indicators such as Book Value per Share of 3.69, Current Ratio of 17.42 or Debt to Equity Ratio of 0.0554. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules. It can also supplement various Immunovant Technical models. Check out Risk vs Return Analysis.

Immunovant Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets445.1 M412.5 M90.9 M
Increasing
Slightly volatile
Cash and Equivalents431.7 M400.1 M82.9 M
Increasing
Slightly volatile
Property Plant and Equipment Net3.8 M3.5 M649.3 K
Increasing
Slightly volatile
Tax Assets3.6 M3.5 M3.1 M
Increasing
Slightly volatile
Trade and Non Trade Payables2.6 M2.4 M986.1 K
Increasing
Slightly volatile
Total Liabilities19.3 M21 M9.5 M
Increasing
Slightly volatile
Shareholders Equity422.4 M391.5 M81.2 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(305.8 K)(298 K)207.8 K
Decreasing
Slightly volatile
Current Assets441.3 M409 M89.4 M
Increasing
Slightly volatile
Assets Non Current2.8 M3.5 M1.5 M
Increasing
Slightly volatile
Current Liabilities17.7 M18.8 M9.2 M
Increasing
Slightly volatile
Liabilities Non CurrentMM2.2 M
Decreasing
Slightly volatile
Total Debt3.1 M3.1 M3.4 M
Decreasing
Slightly volatile
Debt Current1.1 M1.1 M1.2 M
Decreasing
Slightly volatile
Debt Non CurrentMM2.2 M
Decreasing
Slightly volatile
Shareholders Equity USD422.4 M391.5 M81.2 M
Increasing
Slightly volatile
Cash and Equivalents USD431.7 M400.1 M82.9 M
Increasing
Slightly volatile
Total Debt USD3.1 M3.1 M3.4 M
Decreasing
Slightly volatile

Immunovant Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General and Administrative Expense32.4 M39.5 M9.5 M
Increasing
Slightly volatile
Research and Development Expense63.6 M68.6 M34.3 M
Increasing
Slightly volatile
Operating Expenses96 M108.1 M43.8 M
Increasing
Slightly volatile
Interest Expense559.2 K562.5 K614.3 K
Decreasing
Slightly volatile
Income Tax Expense(367.4 K)(358 K)(38.1 K)
Decreasing
Slightly volatile
Weighted Average Shares75.7 M87.8 M33.9 M
Increasing
Slightly volatile
Weighted Average Shares Diluted75.7 M87.8 M33.9 M
Increasing
Slightly volatile

Immunovant Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing310.8 M383.1 M96.8 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (3.3 M)(3.2 M)31.1 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares418.1 M387.5 M90.5 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents323.2 M299.6 M64.9 M
Increasing
Slightly volatile
Share Based Compensation15.1 M18.8 M4.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.1 M998 K182.1 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Invested Capital35.1443.5125.5267
Increasing
Slightly volatile
Price to Book Value4.924.0148.5289
Decreasing
Slightly volatile
Debt to Equity Ratio0.05540.0540.6857
Decreasing
Slightly volatile
Current Ratio17.4221.7895.3151
Increasing
Slightly volatile
Book Value per Share3.694.4611.109
Increasing
Slightly volatile
Tangible Assets Book Value per Share3.994.71.4031
Increasing
Slightly volatile

Immunovant Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization1.5 B1.6 B991.3 M
Increasing
Slightly volatile
Enterprise Value1.2 B1.2 B822 M
Increasing
Slightly volatile
Invested Capital(3.2 M)(3 M)(798 K)
Decreasing
Slightly volatile
Average Equity324 M378 M103.5 M
Increasing
Slightly volatile
Average Assets358.3 M397.4 M161.1 M
Increasing
Slightly volatile
Invested Capital Average(2.5 M)(2.5 M)44 M
Decreasing
Slightly volatile
Tangible Asset Value445.1 M412.5 M90.9 M
Increasing
Slightly volatile
Working Capital421 M390.2 M80 M
Increasing
Slightly volatile

Immunovant Fundamental Market Drivers

Short Percent Of Float7.30%
Forward Price Earnings-5.94
Shares Short Prior Month5.12M
Average Daily Volume Last 10 Day504.83k
Average Daily Volume In Three Month535.41k
Date Short Interest15th of September 2021
Fifty Day Average8.60
Two Hundred Day Average11.84

Immunovant Upcoming Events

Upcoming Quarterly Report15th of February 2022
Next Earnings Report7th of June 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of June 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunovant without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunovant using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Tools for Immunovant Stock

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go